» Articles » PMID: 28963139

PI3Kγ Activates Integrin α and Promotes Immune Suppressive Myeloid Cell Polarization During Tumor Progression

Overview
Date 2017 Oct 1
PMID 28963139
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Immunosuppressive myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) accumulate in tumors where they inhibit T cell-mediated antitumor immune responses and promote tumor progression. Myeloid cell PI3Kγ plays a role in regulating tumor immune suppression by promoting integrin α-dependent MDSC recruitment to tumors and by stimulating the immunosuppressive polarization of MDSCs and TAMs. Here, we show that integrin α promotes immunosuppressive polarization of MDSCs and TAMs downstream of PI3Kγ, thereby inhibiting antitumor immunity. Genetic or pharmacological suppression of either PI3Kγ or integrin α blocked MDSC recruitment to tumors and also inhibited immune suppressive myeloid cell polarization, thereby reducing expression of IL10 and increasing expression of IL12 and IFNγ within tumors. Inhibition of PI3Kγ or integrin α within tumors stimulated dendritic cell and CD8 T-cell recruitment and maturation, as well as tumor cell cytotoxicity , thereby inhibiting tumor growth. As blockade of PI3Kγ or integrin α prevents accumulation of MDSC and reduces myeloid cell expression of immunosuppressive factors that stimulate tumor immune escape, these results highlight PI3Kγ and integrin α as targets for the design of cancer therapeutics. .

Citing Articles

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.

Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.

PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.


ITGA4 as a potential prognostic and immunotherapeutic biomarker in human cancer and its clinical significance in gastric cancer: an integrated analysis and validation.

Zhang J, Wang G, Liu J, Tang F, Wang S, Li Y Front Oncol. 2025; 15:1513622.

PMID: 40012546 PMC: 11860100. DOI: 10.3389/fonc.2025.1513622.


Targeting PI3K-gamma in myeloid driven tumour immune suppression: a systematic review and meta-analysis of the preclinical literature.

Xu H, Russell S, Steiner K, ONeill E, Jones K Cancer Immunol Immunother. 2024; 73(10):204.

PMID: 39105848 PMC: 11303654. DOI: 10.1007/s00262-024-03779-2.


Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule.

Kelly L, Rutter J, Lin K, Ling F, Duchmann M, Latour E Nat Cancer. 2024; 5(7):1082-1101.

PMID: 38816660 PMC: 11778622. DOI: 10.1038/s43018-024-00782-5.


Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities.

Qian Y, Yin Y, Zheng X, Liu Z, Wang X Biomark Res. 2024; 12(1):1.

PMID: 38185636 PMC: 10773124. DOI: 10.1186/s40364-023-00549-7.


References
1.
Sasaki T, Irie-Sasaki J, Jones R, Stanford W, Bolon B, Wakeham A . Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science. 2000; 287(5455):1040-6. DOI: 10.1126/science.287.5455.1040. View

2.
Hirsch E, Katanaev V, Garlanda C, Azzolino O, Pirola L, Silengo L . Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science. 2000; 287(5455):1049-53. DOI: 10.1126/science.287.5455.1049. View

3.
Schumacher K, Haensch W, Roefzaad C, Schlag P . Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001; 61(10):3932-6. View

4.
Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

5.
Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2):133-46. DOI: 10.1038/nri1001. View